Frontier Bio vs Emulate
Side-by-side comparison of AI visibility scores, market position, and capabilities
Frontier Bio develops living vascular grafts and bioprinted human tissue for pharmaceutical testing and future organ donation, using a 4D self-assembly approach to create complex lung, brain, and vascular microtissues without animal testing.
About
Frontier Bio is a biotechnology company focused on tissue engineering and regenerative medicine, developing engineered human tissues as alternatives to animal models in pharmaceutical testing and as the foundational building blocks for future transplantable organs. The company combines advanced bioprinting techniques with stem cell self-assembly — a process it describes as "4D printing" — in which cells are guided to autonomously organize into complex tissue structures, such as the branching alveolar architecture of human lung tissue.
Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.
About
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.